See "Risk Factors" beginning on page 5.PRICE$A SHAREPrice to PublicUnderwriting Discounts and CommissionsProceeds to AffymaxPer Share$$$Total$$$We have granted the underwriters the right to purchase up to an additional 525,000 shares of common stock to cover over-allotments.The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities, or determined if this
recombinant EPO-based products which are the only currently marketed ESAs. As a result, we believe Hematide has the potential to offer both better care for patients and reduced cost and
"Innotide," and "Affymax and logo." We have applied in certain other countries to register the trademarks: "Avixis," "Hematide" and "Innotide."2THE OFFERINGCommon stock offered by us3,500,000 sharesCommon stock to be outstanding after this offering14,013,789 sharesUse of proceedsWe plan to use the net proceeds from this offering to support research and development activities for Hematide and other product candidates; to fund activities in preparation for the potential commercial launch of Hematide; and for working capital
Financial Condition and Results of Operations," appearing elsewhere in this prospectus.Nine Months Ended September 30,Period from July 20, 2001 (inception) to September 30, 2006Year Ended December 31,20032004200520052006(unaudited)(unaudited)(in thousands, except for per share data)Statements of Operations Data:Revenue$225$151$74$67$4,991$5,544Operating expenses:Research and development13,66017,33824,05116,84941,228119,051General and administrative4,9534,93110,0326,16311,34339,314Amortization of intangible assets6,107————14,471Impairment of assets4,224————4,224Total operating expenses28,94422,26934,08323,01252,571177,060Loss from operations(28,719)(22,118)(34,009)(22,945)(47,580)(171,516)Interest income3574391,4137883,5406,915Interest expense(7)—(29)(22)(63)(149)Other income (expense), net1722814935(22)164Net loss(28,197)(21,398)(32,576)(22,144)(44,125)(164,586)Accretion of mandatorily redeemable convertible preferred stock(164)(105)(597)(182)(624)(1,708)Net loss attributable to common stockholders$(28,361)$(21,503)$(33,173)$(22,326)$(44,749)$(166,294)Basic and diluted net loss per common share:Historical$(103.10)$(70.39)$(101.65)$(69.17)$(46.50)Pro forma (unaudited)$(4.33)$(4.47)Weighted-average number of shares used to compute basic and diluted net loss per common share:Historical275305326323962Pro forma (unaudited)7,5269,878As of September 30, 2006 (unaudited)ActualPro Forma(1)(2)Pro FormaAs Adjusted(3)(in thousands)Balance Sheet Data:Cash, cash equivalents and short-term investments$142,128$142,128$214,393Working capital140,788140,588212,853Total assets150,562150,362222,627Long term capital lease obligations215215215Deficit accumulated during the development stage(164,586)(164,786)(164,786)Redeemable preferred stock156,537——Total stockholders' equity (deficit)(130,473)25,86498,129(1)Reflects
successfully commercialized.Hematide, which is our only product candidate in clinical development, is in multiple Phase 2 clinical trials for the treatment of anemia associated with
adverse impact on our business as we would have to incur substantial expense and it would take a significant amount of time and resources to bring our other product candidates to market.We have initiated binding arbitration and related litigation with Johnson & Johnson Pharmaceutical Research & Development,
technical, legal and management personnel have been and will continue to be diverted as a result of this dispute.Our commercial success depends upon attaining significant market acceptance of Hematide among physicians, patients, health care payors
competing ESA products could potentially limit the market opportunity for Hematide, and adversely impact our ability to generate revenues.Currently, the Centers for Medicare and Medicaid Services, or CMS, reimburses healthcare providers for use of ESAs at a rate of average sales price plus a 6% margin to the provider, or
settings than end stage renal disease patients receiving treatment at dialysis centers.In addition, market acceptance of ESAs as well as our lead product candidate, Hematide, and any future product candidates by physicians, healthcare payors and patients will depend on a
additional competition for Hematide and could drive its price down, which may adversely affect our revenues.8Any failure or delay in completing clinical trials for our product candidates could severely harm our business.Each of our product candidates must undergo extensive preclinical studies and clinical trials as a condition to regulatory approval.
unable to predict what clinical trials the FDA will require us to conduct, which could result in additional delays in bringing our product candidates to market.
collaboration agreements.Our existing product candidates will require extensive additional clinical evaluation, regulatory approval, significant marketing efforts and substantial investment before they can
product candidates in a cost-effective manner or on a timely basis.The commercial success of our collaborations depends in part on the development and marketing efforts of our collaboration partners, over
encounter difficulties in managing our growth and expanding our operations successfully.As we advance our product candidates through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities
review, which may result in significant additional expense and limit our ability to commercialize our future products.Any regulatory approvals that we or our collaboration partners receive for our product candidates may also be subject to limitations on the indicated uses for
obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our future product to other available
a result of new information, future events or otherwise, except as required by law.25USE OF PROCEEDSWe estimate that the net proceeds from the sale of the shares of our common stock in this offering will be approximately $72.3 million, or approximately
regulatory milestone payments, reimbursement of third party U.S. clinical development expenses, product profit share revenues (as co-promotion revenues) and royalties.In February 2006, we issued an exclusive license to Takeda for the development and commercialization of Hematide in Japan.
for the lead product candidates of the comparable companies chosen (using estimates from independent market research organizations), the level of risk associated with the clinical trials for Hematide,
initially developing this product candidate for the treatment of anemia in renal disease and oncology because of the proven clinical and regulatory pathway and commercial potential for Hematide in